Management of relapsed/refractory DLBCL
Best Practice & Research Clinical Haematology · 2018-09 · 31 (3) · 209-216
DOI: 10.1016/j.beha.2018.07.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Haematology, 2018-09. Verfasst von Clémentine Sarkozy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France; British Columbia Cancer Centre for Lymphoid Cancer and the University of Bri…. Hauptthemen laut MEDLINE: Stem Cell Transplantation. Die Arbeit wurde bisher 130-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
Diffuse large B cell lymphoma represents the most common type of non-Hodgkin lymphoma. Although the curability rate is high, around 40% of patients will relapse or exhibit refractory disease. To obtain long-term disease-free survival after relapse, an intensive salvage regimen followed by autologous steam cell transplant remains the standard of care. However, more than 60% of patients will be transplant ineligible, presenting a therapeutic challenge. In this setting, there is no definitive standard approach, as management should be individualized according to patient tolerance. Importantly, these transplant ineligible patients are ideal for consideration of novel agents. In this review, we will discuss the incidence, outcome, and management of relapsed and refractory DLBCL, as well as explore some of the novel agents in development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France; British Columbia Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada.
- British Columbia Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: lsehn@bccancer.bc.ca.
Zitieren
APA
Sarkozy, C., & Sehn, L. H. (2018). Management of relapsed/refractory DLBCL. Best Practice & Research Clinical Haematology, 31(3), 209-216. https://doi.org/10.1016/j.beha.2018.07.014
Vancouver
Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Practice & Research Clinical Haematology. 2018;31(3):209-216. doi:10.1016/j.beha.2018.07.014
BibTeX
@article{Sarkozy2018,
author = {Sarkozy, Clémentine and Sehn, Laurie H},
title = {Management of relapsed/refractory DLBCL},
journal = {Best Practice & Research Clinical Haematology},
year = {2018},
volume = {31},
number = {3},
pages = {209--216},
doi = {10.1016/j.beha.2018.07.014}
}
EUVIMED